Shares of Viking Therapeutics (VKTX) trading down on concerns stemming from Altimmune’s (ALT) "underwhelming" date this morning, William Blair the analyst tells investors in a research note. The analyst emphasizes that Viking’s VK2735 is a dual GLP-1/GIP agonist on track to have first-in-human data in obese individuals later this morning or in April. In contrast, Altimmune’s pemvidutide is a dual GLP-1/glucagon receptor agonist with a different mechanism of action, and therefore has limited read-through to Viking. In addition, Blair says the bullish thesis on Viking remains on its non-alcoholic steatohepatitis asset, VK2809. It is a buyer of the stock on the selloff and keeps an Outperform rating on the name.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics initiated with a Buy at Stifel
- William Blair biotech analysts to hold an analyst/industry conference call
- Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
- Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update